Market Research Logo

Contrast Agents/Media Global Market – Forecast To 2025

Contrast Agents/Media Global Market – Forecast To 2025

Chemical substances that improve the visibility of specific organs, tissues or blood vessel during a diagnostic imaging investigation are known as contrast agents. These substances are administered directly through veins, arteries, and joints or consumed orally. X-ray and computed tomography (CT) imaging exams makes use of iodinated and barium based contrast agents, whereas, Gadolinium-based contrast agents are preferred in MRI (Magnetic Resonance Imaging). These substances improve the reporting or accuracy of how internal structures of body are working and any associated abnormalities. Ultrasound scans makes use of special contrast agents called microbubbles which strongly interact with the ultrasound beam and enhances the details of heart, liver and kidney.

As estimated by IQ4I Research, the contrast agent global market is expected to grow at single digit CAGR to reach $6,879.0 million by 2025. The contrast agent global market by molecule is segmented into Iodine based [Ionic (Monomeric and Dimeric), Non-Ionic (Monomeric and Dimeric)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], microbubble based contrast agent and others which include Barium, iron and dyes. Iodine-based contrast agent market held the largest market revenue in 2018 and microbubble segment is growing rapidly at double digit CAGR from 2018 to 2025 due to expansion in disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. Non-Ionic Iodine-based contrast agent market accounted the largest share. Non-ionic iodine contrast agents are used more because of lower osmolality, they are better tolerated and another advantage is that, they appear to have less toxicity. Ionic Iodine based contrasts are further segmented by its chemical structure into monomers and dimers. Monomers market accounted for the largest share. Non-Ionic Iodine based contrasts are further segmented by its chemical structure into monomeric and dimeric. Monomerics market accounted the largest share as they are safer and tolerable when compared to ionic contrast agent and low osmolar agents do not dissociate into a particle in solution and helps in reducing the neurotoxicity.

The contrast agents market by modality is segmented into X-Ray/CT, MRI and Ultrasound. X-Ray/CT market held the largest market revenue in 2018 and ultrasound segment is growing rapidly at double digit CAGR from 2018 to 2025 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of urinary tract.

The contrast agents market by applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, urology and others which include neck, liver and salivary gland imaging. Cardiovascular market accounted for the largest share and is the fastest growing market from 2018 to 2025 due to increase in a number of cardiac imaging procedures using Iodine, Gadolinium and microbubble contrast agents. Contrast agents market by route of administration is segmented into intravascular, oral, rectal and others which include intraosseous, intrathecal and intravesicle. Intravascular route of administration accounted for largest share and is the fastest growing market due to increase in incidence and prevalence of cardiovascular, cancer, neurology, nephrology related conditions which require Iodine, Gadolinium and microbubble contrast agent to be administered intravascular.

Contrast agents market by imaging is segmented into diagnostic and interventional imaging. Diagnostic imaging market held the largest market revenue and interventional imaging segment is growing at fast/rapidly at double digit CAGR from 2018 to 2025 due to increase in image guide procedures and increase in aging population who usually opt minimally invasive procedures.

Contrast agents market based on the end-user market is segmented into hospitals, diagnostic & ambulatory surgical centers and other which include academic and research institutes. Hospitals market accounted largest share in 2018 as there is a rise in demand for the diagnosis and interventional treatment of diseases using CT or X-Ray, MRI and ultrasound imaging procedures. Diagnostic & Ambulatory surgical centers is the fastest growing segment with mid single digit CAGR from 2018 to 2025 due to increase in number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of abdomen, GI tract) and obstetrics & gynecology (hysterosalpingography).

Geographical wise, North America region commanded the largest revenue in 2018. Favorable reimbursement coverage and increase in incidence and prevalence of diseases conditions due to change in lifestyle, obesity has led the market growth in this region. However, Asia-Pacific region is the second leading market for contrast agents and is expected to grow at mid single CAGR from 2018 to 2025 due to increased healthcare awareness, economic growth, large patient pool and rising aged population.

The contrast agent global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players of the contrast agent market are GE Company (GE Healthcare) (U.S.), Bayer Group (Germany), Guerbet (France), Taejoon Pharm Co. Ltd., (South Korea), Beijing Beilu Pharmaceuticals Company Limited (China), Bracco Group (Italy), Fujifilm Holding Corporation (Japan), Sanochemia Pharmazeutika AG (Austria), Dongkook Lifescience (Korea), Lantheus medical imaging (U.S.) and Fujipharma Co. Ltd (Japan).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)


1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 REPORT SCOPE
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET CRACKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing demand for diagnostic and interventional radiology procedures
3.3.1.2 Increase in incidence and prevalence of disease conditions
3.3.1.3 Increase in aging population
3.3.1.4 Expansion in indications of contrast media market
3.3.1.5 The growth of medical imaging technologies in emerging markets
3.3.1.6 Increasing research activities for contrast agents
3.3.1.7 Favorable reimbursement
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Side effect associated with contrast agents.
3.3.2.2 Shortage of radiologist.
3.3.2.3 Availability of alternative products
3.3.2.4 Stringent regulations for contrast agents.
3.4 REGULATORY GUIDELINES
3.4.1 UNITED STATES
3.4.2 EUROPE
3.4.3 CHINA
3.4.4 JAPAN
3.4.5 INDIA
3.5 REIMBURSEMENT SCENARIO
3.5.1 REIMBURSEMENT TABLE
3.6 UPCOMING TECHNOLOGY
3.7 CLINICAL TRIALS
3.8 PATENT TRENDS
3.9 SUPPLY CHAIN ANALYSIS
3.10 PORTER’S FIVE FORCE ANALYSIS
3.10.1 THREAT OF NEW ENTRANTS
3.10.2 THREAT OF SUBSTITUTES
3.10.3 BARGAINING POWER OF SUPPLIERS
3.10.4 BARGAINING POWER OF BUYERS
3.10.5 RIVALRY AMONG EXISTING COMPETITORS
3.11 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.11.1 CONTRAST AGENT GLOBAL MARKET
3.11.2 X-RAY/CT CONTRAST AGENTS MARKET
3.11.3 MRI CONTRAST AGENT MARKET
3.11.4 ULTRASOUND BASED CONTRAST AGENT MARKET
3.12 CONTRAST AGENT GLOBAL CONSUMPTION
4 CONTRAST AGENTS GLOBAL MARKET, BY MOLECULE
4.1 INTRODUCTION
4.2 IODINE BASED CONTRAST MEDIA
4.2.1 IODINE BASED IONIC CONTRAST MEDIA
4.2.1.1 Monomers
4.2.1.2 Dimer
4.2.2 IODINE BASED NON-IONIC CONTRAST MEDIA
4.2.2.1 Monomer
4.2.2.2 Dimer
4.3 GADOLINIUM-BASED CONTRAST MEDIA
4.3.1 MACROCYCLIC
4.3.1.1 Ionic
4.3.1.2 Non-ionic
4.3.2 LINEAR
4.3.2.1 Ionic
4.3.2.2 Non-ionic
4.4 MICROBUBBLE BASED CONTRAST MEDIA
4.5 OTHER CONTRAST MEDIA
5 CONTRAST AGENTS GLOBAL MARKET, BY MODALITY
5.1 INTRODUCTION
5.2 X-RAY/COMPUTED TOMOGRAPHY (CT)
5.3 MAGNETIC RESONANCE IMAGING (MRI)
5.4 ULTRASOUND
6 CONTRAST AGENTS GLOBAL MARKET, BY APPLICATION
6.1 INTRODUCTION
6.2 CARDIOVASCULAR
6.3 CANCER
6.4 GASTROINTESTINAL
6.5 MUSCULOSKELETAL
6.6 NEUROLOGY
6.7 NEPHROLOGY
6.8 OBSTETRICS AND GYNECOLOGY
6.9 UROLOGY
6.10 OTHERS
7 CONTRAST AGENTS GLOBAL MARKET, BY ROUTE OF ADMINISTRATION
7.1 INTRODUCTION
7.2 INTRAVASCULAR
7.3 ORAL
7.4 RECTAL
7.5 OTHERS
8 CONTRAST AGENTS GLOBAL MARKET, BY IMAGING
8.1 INTRODUCTION
8.2 DIAGNOSTIC IMAGING
8.3 INTERVENTIONAL IMAGING
9 CONTRAST AGENT GLOBAL MARKET, BY END-USERS
9.1 INTRODUCTION
9.2 HOSPITAL
9.3 DIAGNOSTIC & AMBULATORY SURGICAL CENTERS
9.4 OTHER END-USER
10 REGIONAL ANALYSIS
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 THE U.S.
10.2.2 OTHERS
10.3 EUROPE
10.3.1 GERMANY
10.3.2 U.K.
10.3.3 FRANCE
10.3.4 OTHERS
10.4 ASIA-PACIFIC
10.4.1 JAPAN
10.4.2 CHINA
10.4.3 KOREA
10.4.4 OTHERS
10.5 REST OF THE WORLD
10.5.1 BRAZIL
10.5.2 REST OF LATIN AMERICA
10.5.3 MIDDLE EAST AND OTHERS
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 APPROVALS
11.3 OTHER KEY DEVELOPMENT
11.4 COLLABORATION
11.5 PARTNERSHIP
11.6 AGREEMENT
11.7 NEW PRODUCT LAUNCH
12 MAJOR PLAYER PROFILES
12.1 BAYER GROUP
12.1.1 OVERVIEW
12.1.2 FINANCIALS
12.1.3 PRODUCT PORTFOLIO
12.1.4 KEY DEVELOPMENTS
12.1.5 BUSINESS STRATEGY
12.1.6 SWOT ANALYSIS
12.2 BEIJING BEILU PHARMACEUTICAL CO., LTD
12.2.1 OVERVIEW
12.2.2 FINANCIALS
12.2.3 PRODUCT PORTFOLIO
12.2.4 KEY DEVELOPMENTS
12.2.5 BUSINESS STRATEGY
12.2.6 SWOT ANALYSIS
12.3 BRACCO GROUP
12.3.1 OVERVIEW
12.3.2 FINANCIALS
12.3.3 PRODUCT PORTFOLIO
12.3.4 KEY DEVELOPMENTS
12.3.5 BUSINESS STRATEGY
12.3.6 SWOT ANALYSIS
12.4 DONGKOOK LIFE SCIENCE
12.4.1 OVERVIEW
12.4.2 FINANCIALS
12.4.3 PRODUCT PORTFOLIO
12.4.4 KEY DEVELOPMENTS
12.4.5 BUSINESS STRATEGY
12.4.6 SWOT ANALYSIS
12.5 FUJIFILM HOLDINGS CORPORATION
12.5.1 OVERVIEW
12.5.2 FINANCIALS
12.5.3 PRODUCT PORTFOLIO
12.5.4 KEY DEVELOPMENTS
12.5.5 BUSINESS STRATEGY
12.5.6 SWOT ANALYSIS
12.6 FUJIPHARMA CO LTD
12.6.1 OVERVIEW
12.6.2 FINANCIALS
12.6.3 PRODUCT PORTFOLIO
12.6.4 KEY DEVELOPMENTS
12.6.5 BUSINESS STRATEGY
12.6.6 SWOT ANALYSIS
12.7 GE COMPANY (GE HEALTHCARE)
12.7.1 OVERVIEW
12.7.2 FINANCIALS
12.7.3 PRODUCT PORTFOLIO
12.7.4 KEY DEVELOPMENTS
12.7.5 BUSINESS STRATEGY
12.7.6 SWOT ANALYSIS
12.8 GUERBET
12.8.1 OVERVIEW
12.8.2 FINANCIALS
12.8.3 PRODUCT PORTFOLIO
12.8.4 KEY DEVELOPMENTS
12.8.5 BUSINESS STRATEGY
12.8.6 SWOT ANALYSIS
12.9 LANTHEUS MEDICAL IMAGING INC.
12.9.1 OVERVIEW
12.9.2 FINANCIALS
12.9.3 PRODUCT PORTFOLIO
12.9.4 KEY DEVELOPMENTS
12.9.5 BUSINESS STRATEGY
12.9.6 SWOT ANALYSIS
12.10 SANOCHEMIA PHARMACEUTICAL AG
12.10.1 OVERVIEW
12.10.2 FINANCIALS
12.10.3 PRODUCT PORTFOLIO
12.10.4 KEY DEVELOPMENTS
12.10.5 BUSINESS STRATEGY
12.10.6 SWOT ANALYSIS
12.11 TAEJOON PHARM CO., LTD
12.11.1 OVERVIEW
12.11.2 FINANCIALS
12.11.3 PRODUCT PORTFOLIO
12.11.4 KEY DEVELOPMENTS
12.11.5 BUSINESS STRATEGY
12.11.6 SWOT ANALYSIS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report